Edmonton, AB, Canada. April 30, 2021 /CNW/ – Kaiser Day Cannaceuticals, a leading medical cannabis solutions provider has announced its plans to enter the Canadian medical cannabis marketplace.
Kaiser Day Cannaceuticals creates pharmaceutical-grade, terpene-rich, full-spectrum cannabis medicines scientifically designed to achieve specific effects for medical cannabis patients. Kaiser Day’s proprietary formulations are created using the latest, cutting-edge clinical research on full-spectrum cannabinoids, terpenes, and their synergistic effects on the human body’s endocannabinoid system.
Research studies have shown vaporization to be the most precise dosing method for medical cannabis patients. Vaporizing cannabinoids is extremely efficient and increases the bioavailability of the medication up to 95% whilst eliminating the toxic fumes and chemicals generated by smoking cannabis. The effects of vaping medical cannabis are nearly instantaneous, allowing you to titrate doses according to your individual needs more easily.
The Summer 2021 product launch will feature five, effect-specific vaporizable medical cannabis products. Each Kaiser Day formulation contains full-spectrum cannabinoids including THC, CBD, CBG, CBDV, CBC, and CBN and effect-specific terpene blends in five pharmaceutical-grade, effect-specific formulations: Relief, Bliss, Relax, Sleep and the newest, high-THC blend, Ascend.
Kaiser Day Cannaceuticals is an international cannabis pharmaceutical company and the developer of several clinically-proven, pharmaceutical-grade cannabis products. The company aspires to be one of the world’s most trusted cannabis pharmaceutical companies with aggressive plans to bring its scientifically-formulated, clinically-proven vaporisable medical cannabis products to countries whose federal laws permit the use and prescription of cannabis extracts for medical or therapeutic purposes.
For further information, please contact:
Kaiser Day Cannaceuticals